Tuesday - May 12, 2026
Johnson & Johnson Reinforces Its Leadership in Advancing Neuropsychiatry With New Portfolio and Pipeline Data at APA and ASCP
May 12, 2026
RARITAN, New Jersey, May 12 -- Johnson and Johnson Innovative Medicine issued the following news release on May 11, 2026:

* * *

Johnson & Johnson reinforces its leadership in advancing neuropsychiatry with new portfolio and pipeline data at APA and ASCP

Oral presentations feature CAPLYTA(R) long-term data assessing relapse risk reduction in schizophrenia and new seltorexant analyses in major depressive disorder (MDD) with insomnia symptoms

. . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products